Overview
N-Acetylcysteine (NAC) is a glutathione precursor and glutamatergic modulator that addresses two key features of ASD pathophysiology: oxidative stress and excitatory-inhibitory imbalance. A pilot RCT demonstrated large effect sizes for irritability reduction.
Mechanism
- Glutathione restoration: NAC is the rate-limiting precursor for glutathione (GSH) synthesis; GSH is consistently depleted in ASD
- Toxic metal chelation support: Restored GSH facilitates conjugation and excretion of Hg, Pb, and Cd — metals that displace essential cofactors (Primitive 3: mis-metallation)
- Glutamate modulation: NAC activates the cystine-glutamate antiporter, reducing synaptic glutamate and restoring excitatory-inhibitory balance
Clinical Evidence
Pilot RCT (n=33, 12 weeks): NAC significantly improved the Aberrant Behavior Checklist (ABC) irritability subscale with a large effect size (d=0.96, P<0.01). Well-tolerated with mild GI side effects.
Clinical Considerations
- Dose range in studies: 900-2700 mg/day in divided doses
- GI side effects (nausea, loose stools) are the most common complaint
- May be combined with other ASD interventions targeting the microbiome